Bisoprolol for pericarditis -Phase III randomized controlled clinical trial in patients with acute or recurrent pericarditis

2025-523015-11-00 · tracked via the Priya Life Science EU tracker

Sponsor

Azienda Sanitaria Universitaria Friuli Centrale

Sponsor type

Hospital/Clinic/Other health care facility

Therapeutic area

Cardiovascular Diseases

Decision date

27/10/2025

Enrollment target

300

Sites

Italy

Condition studied

Pericarditis

Investigational medicinal product(s)

BISOPROLOL

Eligibility

Age group

65+ years, 18-64 years

Sex

Female, Male

Primary endpoint

The aim of this study is to evaluate the effectiveness of beta-blocking therapy with bisoprolol in reduce the persistence of pericarditis symptoms at 2 and 4 weeks and the frequency of relapses at 12 months

Endpoint detail

Secondary endpoints: persistence of symptoms at 1 month. Frequency of relapses at 12 months. Additional secondary analysis: correlation between baseline C-reactive protein values and heart rate at first observation

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523015-11-00 on CTIS ↗ ← All trials in the EU